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Abstract.	  
Aim:	   To	   review	   and	   summarize	   available	   data	   on	   the	   possible	   influence	   of	   sympathetic	  
nervous	  system	  in	  Bladder	  Pain	  syndrome/Interstitial	  Cystitis	  (BPS/IC)	  pathogenesis.	  
Methods:	  A	   search	   for	   relevant	  articles	  was	  performed	   in	   the	  Medline,	  EMBASE,	  Web	  of	  
Science	  and	  Cochrane	  Library	  electronic	  databases.	  Only	  English	  language	  publications	  since	  
1900	  to	  January	  2014	  were	  selected.	  
Results:	   The	   true	   causes	   of	   BPS/IC	   remain	   elusive.	   However,	   several	   causes	   have	   been	  
recently	   proposed,	   including	   epithelial	   dysfunction,	   deregulation	   of	   the	   immune	   response	  
and	   neurogenic	   inflammation.	   The	   contribution	   of	   the	   of	   sympathetic	   nervous	   system	   to	  
BPS/IC	   has	   been	   traditionally	   disregarded	   but	   there	   is	   strong	   evidence	   for	   a	   sympathetic	  
role.	   Indeed,	   published	   reports	   show	   that	   rat	   models	   of	   chronic	   adrenergic	   stimulation	  
reproduced	  many	  of	  clinical	  aspects	  and	  typical	  histological	  findings	  of	  BPS/IC	  patients.	  
Conclusion:	   The	   reports	   found	   and	   analyzed	   in	   the	   present	   review	   indicate	   that	   several	  
factors	   may	   contribute	   to	   the	   etiology	   of	   BPS/IC.	   Particularly,	   the	   sympathetic	   nervous	  
system	  emerges	  as	  one	  of	  the	  main	  contributors	  to	  BPS/IC	  pathogenesis.	   Its	   influence	  may	  
underlie	  at	  least	  some	  of	  the	  multiple	  problems	  reported	  by	  BPS/IC	  patients.	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Introduction	  
Bladder	   pain	   syndrome/interstitial	   cystitis	   (BPS/IC)	   is	   a	   poorly	   defined	   clinical	   condition.	  
The	   prevalence	   in	   USA	   was	   suggested	   to	   reach	   100/100	   000	   women	   (1).	   More	   recent	  
European	  epidemiological	  surveys	  reported	  a	  prevalence	  of	  about	  200-­‐300/100	  000	  women	  
(2).	   No	   cure	   exists	   yet	   for	   this	   disease	   and	   the	   etiology	   is	   unknown.	   The	   initial	   diagnostic	  
criteria	   were	   proposed	   in	   1987	   by	   the	   National	   Institute	   of	   Diabetes	   and	   Kidney	   Disease	  
(NIDDK)	  (3).	  These	  criteria	  are	  now	  obsolete	  as	  they	  miss	  more	  than	  60%	  of	  cases.	  A	  more	  
accurate	  definition	  of	  BPS/IC	  was	  recently	  proposed	  by	  the	  American	  Urological	  Association	  
(AUA)	   for	   diagnosis	   and	   treatment.	  According	   to	   the	  AUA,	  BPS/IC	   is	   characterized	  by:	   “An	  
unpleasant	   sensation	   (pain,	   pressure,	   discomfort)	   perceived	   to	   be	   related	   to	   the	   urinary	  
bladder,	  associated	  with	  lower	  urinary	  tract	  symptom(s)	  of	  more	  than	  6	  weeks	  duration,	  in	  
the	  absence	  of	  infection	  or	  other	  identifiable	  causes’’	  (4).	  
BPS/IC	  may	   be	   accompanied	   by	   other	   pathological	   conditions,	   not	   necessarily	   bladder	   –
related.	   The	   most	   common	   comorbidities	   associated	   to	   BPS/IC	   include	   irritable	   bowel	  
syndrome	  (IBS),	  fibromyalgia,	  chronic	  fatigue	  syndrome,	  Sjogren’s	  syndrome,	  chronic	  pelvic	  
pain,	  anxiety	  disorders,	  migraine,	  allergies,	  asthma,	  sleep	  disorders	  and	  other	  syndromes	  not	  
related	   to	   the	   bladder	   (5).	   Epidemiologic	   studies	   suggest	   that	   only	   7%	   of	   BPS/IC	   patients	  
have	  none	  of	  those	  co-­‐morbid	  syndromes	  (6).	  Conversely,	  patients	  with	  these	  non-­‐bladder	  
syndromes	  have	  an	  higher	  probability	  of	  developing	  BPS/IC	  in	  the	  future,	  and	  this	  probability	  
is	  proportional	  to	  the	  number	  of	  associated	  syndromes	  (7).	  Interestingly,	  these	  non-­‐bladder	  
syndromes	  shares	  many	  of	  the	  characteristically	   findings	  of	  BPS/IC,	  such	  as,	   the	  worsening	  
during	  stressful	  situations	  and	  the	  possible	  involvement	  of	  urothelial	  and	  mast	  cells	  as	  well	  
as	  the	  neurotrophins	  in	  their	  pathogenesis.	  These	  common	  features	  may	  suggest	  there	  is	  a	  
common	  factor	  in	  their	  pathophysiology.	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The	  true	  causes	  of	  BPS/IC	  remain	  elusive,	  with	  a	  variety	  of	  possibilities	  being	  indicated	  by	  
several	  clinical	  and	  experimental	  studies.	  Therefore,	  the	  aim	  of	  this	  study	  was	  to	  review	  and	  
summarize	  available	  data	  on	  this	  matter.	  	  	  
	  
Methods	  
A	  search	  for	  relevant	  articles	  was	  performed	  in	  the	  Medline,	  EMBASE,	  Web	  of	  Science	  and	  
Cochrane	   Library	   electronic	   databases	   with	   different	   combinations	   of	   the	   following	   key-­‐
terms:	   “Interstitial	   Cystitis”,	   “Bladder	   Pain	   Syndrome”,	   “Painful	   Bladder	   Syndrome”,	  
“Sympathetic	   Nervous	   System”,	   “Adrenergic	   Fibers”,	   “Autonomic	   Nervous	   System”,	  
“Neurotrophins”	   and	   “Mast	   cells”.	   Only	   English	   language	   publications	   since	   1900	   to	   2014	  
January	  were	   included.	  Additionally,	   references	  of	   retrieved	  articles	  were	   scanned	   for	   any	  
potentially	  relevant	  article.	  
	  
Results	  
The	   pathophysiologic	   mechanisms	   underlying	   BPS/IC	   remain	   unclear.	   However,	   several	  
causing	   agents	   have	   been	   proposed	   in	   recent	   years.	   These	   include	   epithelial	   dysfunction,	  
deregulation	  of	  the	  immune	  response	  and	  neurogenic	  inflammation	  (8).	  A	  number	  of	  animal	  
models	  have	  been	  used	  for	  the	  study	  of	  BPS/IC,	  which	  include	  administration	  of	  an	  irritant	  or	  
immune	   stimulant	   (e.g.	   hydrochloric	   acid,	   turpentine,	   protamine	   sulfate,	   mustard	   oil,	  
lipopolysaccharide	   and	   cyclophosphamide).	   In	   addition,	   cats	   with	   with	   feline	   interstitial	  
cystitis	  and	  an	  experimental	  autoimmune	  cystitis	  (EAC)	  murine	  model	  have	  also	  been	  used.	  
These	   animal	   models	   exhibit	   a	   number	   of	   functional	   and	   histological	   alterations	   of	   the	  
bladder,	   comparable	   to	   those	  observed	   in	   in	  human	  BPS/IC	   (9,	  10),	   and	  have	  been	  widely	  
used	  to	  identify	  the	  putative	  cause	  of	  this	  syndrome.	  Available	  results	  point	  towards	  damage	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of	   the	  urothelium,	  mast	   cells	   activation	   in	   the	   submucosa,	   synthesis	  of	  neurotrophins	  and	  
sympathetic	  activation	  as	  key	  factors	  of	  BPS/IC.	  	  	  
	  
Damage	  of	  the	  urothelium:	  	  a	  key	  factor	  in	  BPS/IC.	  
The	  urothelium	   is	   the	   specific	   epithelium	   lining	   of	   the	   distal	   urinary	   track.	   The	   tight	   and	  
adherent	   junctions	   of	   its	   uppermost	   cells,	   the	   umbrella	   cells	   layer,	   together	   with	   a	   thin	  
coating	  mucinous	   layer	  of	  glycosaminoglycans	  and	  glycoproteins,	   form	  an	  effective	  barrier	  
that	   is	   essential	   for	   normal	   bladder	   function	   (11).	   It	   is	   now	   well	   established	   that	   the	  
urothelium	   is	   not	   just	   a	   passive	   barrier.	   The	   close	   anatomical	   relation	   between	   the	  
urothelium	   and	   afferent	   nerves,	   coursing	   in	   the	   lamina	   propria,	   suggests	   an	   interaction	  
between	   them	   (11).	   Following	  mechanical	   or	   chemical	   stimulation,	   urothelial	   cells	   release	  
various	   substances,	   including	   the	   neurotrophin	   nerve	   growth	   factor	   (NGF),	   adenosine	  
triphosphate	   (ATP),	   acetylcholine,	   nitric	   oxide	   and	   prostanoids	   that	   can	   stimulate	  
submucosal	   sensory	  nerves	  and	  cause	  pain	   (12).	  Urothelial	   cells	   also	   respond	   to	   the	   same	  
substances	  either	  in	  an	  autocrine	  fashion	  or	  when	  released	  by	  activated	  nearby	  nerve	  fibres	  
(13),	  which	  may	  lead	  to	  loosening	  of	  intercellular	  junctions	  and	  loss	  of	  urothelial	  integrity.	  A	  
leaky	  urothelium	  has	  been	  observed	  in	  biopsies	  from	  BPS/IC	  patients	  and	  in	  bladder	  samples	  
from	   animal	   models	   of	   this	   disease	   (13).	   The	   increase	   in	   urothelium	   permeability	   allows	  
leaking	  of	  water,	   urea,	   pronociceptive	   and	   inflammatory	   substances,	   present	   in	   the	  urine,	  
into	   the	   bladder	   wall,	   further	   activating	   sensory	   fibres	   and	   immune	   cells	   and	   leading	   to	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Mast	  cell:	  a	  neuroimmunoendocrine	  connection.	  
Mast	  cells	  are	  immune	  cells	  that	  play	  an	  important	  role	  in	  various	  pathological	  conditions.	  
In	  bladder	  biopsies	  from	  BPS/IC	  patients	  the	  density	  of	  activated	  mast	  cells	  was	  upregulated.	  
The	   reason	   for	   this	   may	   reside	   in	   the	   increased	   levels	   of	   stem	   cell	   factor	   (SCF)	   in	   nerve	  
endings	   of	   the	   bladder	   wall,	   an	   chemotactic	   factor	   for	   mast	   cells	   that	   stimulates	   their	  
proliferation	   and	   secretion	   (14).	   In	   the	   bladder,	  mast	   cells	  were	   located	   very	   close	   to	   the	  
submucosa	   nerve	   fibres	   (15),	   suggesting	   an	   interaction	   between	   these	   immune	   cells	   and	  
bladder	   innervation.	   	   When	   activated,	   mast	   cells	   may	   release	   histamine,	   bradykinin,	  
prostaglandins,	   leukotrienes,	   growth	   factors,	   cytokines	   and	   proteases	   (16).	   Most	   sensory	  
fibres	   coursing	   the	   bladder	   wall	   express	   receptors	   to	   these	   proinflammatory	   elements.	  
Activation	   of	   these	   receptors	   leads	   to	   sensitization	   of	   bladder	   sensory	   fibres,	   resulting	   in	  
pain	   and	   urinary	   dysfunction	   present	   in	   BPS/IC	   patients	   and	   experimental	   animal	   with	  
bladder	  inflammation	  (17,	  18).	  In	  turn,	  when	  stimulated,	  these	  fibres	  may	  release	  a	  variety	  
of	  neuropeptides	  that	  act	  on	  mast	  cells,	  further	  stimulating	  the	  activation	  of	  these	  immune	  
cells	   (19).	  Therefore,	   there	   is	  a	   close-­‐knit	   interaction	  between	  mast	   cells	  and	  nerve	   fibres,	  
which	  may	  easily	  become	  uncontrolled	  and	  potentiated	  via	  positive	  feedback	  in	  BPS/IC.	  	  
In	  addition,	  mast	  cells	  may	  also	  be,	  at	  least	  partially,	  accounted	  for	  vascular	  remodelling	  of	  
the	  bladder	  wall,	   also	   known	   to	  occur	   in	  BPS/IC	   (20)	   and	  animal	  models	  of	   this	  pathology	  
(21).	  Activated	  mast	  cells	  are	  known	  to	  release	  tryptase	  that	  leads	  to	  microvascular	  leakage	  
and	   activation	   of	   protease-­‐activated	   receptors	   (PARs),	   expressed	   by	   urothelial	   cells,	   nerve	  
fibres	  and	  immune	  cells,	  resulting	  in	   local	   inflammation	  (22).	  Likewise,	  vascular	  endothelial	  
growth	   factor	   (VEGF),	   also	   released	   by	   mast	   cells,	   may	   induce	   hypervascularity	   and	  
glomerulations	  (20),	  which	  are	  typical	  endoscopic	  findings	  found	  in	  BPS/IC	  patients	  (20,	  22).	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Interestingly,	  VEGF	  may	  further	  sensitize	  bladder	  sensory	  fibres	  as	  they	  express	  receptors	  for	  
this	  vascular	  growth	  factor	  (23).	  	  	  
	  
Neurotrophins	  in	  BPS/IC	  
Neurotrophins	   (NTs)	   are	   trophic	   factors,	   produced	   in	   peripheral	   tissues,	   required	   for	  
neuronal	  survival	  (24).	  The	  urinary	  bladder	  is	  a	  major	  source	  of	  NTs,	  particularly	  of	  the	  two	  
most	   abundant	   NTs,	   Nerve	   Growth	   Factor	   (NGF)	   and	   Brain	   Derived	   Neurotrophic	   Factor	  
(BDNF)	   (24).	   The	   concentration	   of	   NGF	   is	   elevated	   in	   the	   bladder	   and	   urine	   of	   BPS/IC	  
patients,	   positively	   correlating	   with	   the	   severity	   of	   symptoms	   (25).	   Urinary	   BDNF	   is	   also	  
elevated	  (25).	  These	  high	  levels	  of	  NTs	   in	  the	  bladder	  are	  thought	  to	  result	  from	  increased	  
release	  from	  the	  urothelium	  (26)	  and	  from	  immune	  cells	  present	  in	  the	  submucosa	  (27).	  The	  
presence	  of	  higher	  NTs	  levels	  contributes	  to	  the	  sensitization	  of	  bladder	  sensory	  fibres.	  It	  is	  
well	  known	  that	  the	  high	  affinity	  receptors	  of	  NGF	  and	  BDNF,	  tropomyosine-­‐related	  kinase	  A	   (TrkA)	   and	   tropomyosine-­‐related	   kinase	   B	   (TrkB)	   respectively,	   are	   present	   in	   bladder	  
afferents	   (24)	   and	   their	   expression	   and	   activation	   state	   are	   increased	   in	   rats	  with	   chronic	  
cystitis	  (28).	  Upon	  binding	  to	  their	  specific	  receptors,	  NTs	  may	  regulate	  the	  sensitization	  of	  
bladder	   afferents	   either	   by	   direct	   interaction	   with	   membrane	   receptors	   or	   by	   regulating	  
gene	   expression.	   For	   example,	   in	   sensory	   afferents	   NGF	   is	   known	   to	   quickly	   increase	   the	  
expression	  of	  the	  ionic	  channel	  transient	  receptor	  potential	  vanilloid	  receptor	  1	  (TRPV1)	  (29)	  
as	   well	   as	   lowering	   its	   activation	   threshold	   (30).	   In	   addition,	   NGF	   also	   upregulates	   the	  
expression	  of	   the	  neuropeptide	  Substance	  P	  and	  BDNF.	   	  Upon	  stimulation,	   these	  afferents	  
may	   release	   Substance	   P	   in	   the	   bladder,	   activating	   mast	   cells	   (19)	   and	   nerve	   fibres	   (31).	  
BDNF	  is	  released	  at	  the	  spinal	  cord	   level,	  where	   it	  modulates	  excitatory	  neurotransmission	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by	   phosphorylating	   specific	   subunits	   of	   the	   glutamate	   receptor,	   N-­‐methyl-­‐D-­‐aspartate	  
(NMDA),	  via	  intracellular	  activation	  of	  mitogen-­‐activated	  protein	  kinases	  (MAPKs)	  (24)	  .	  	  
Given	  their	   importance	   in	  BPS/IC,	  modulation	  of	  NTs	  has	  been	  proposed	  as	  a	  measure	  to	  
reduce	  pain	  and	   improve	  bladder	  function.	   	  NGF	  modulation	  with	  recombinant	  proteins	  or	  
humanized	  monoclonal	   antibodies	   results	   in	   reduced	   pain	   and	   urinary	   frequency	   (32,	   33).	  
BDNF	  modulation	  has	  only	  been	  tested	   in	  animals	  also	   leading	  to	  a	  significant	  reduction	   in	  
pain	   levels	   and	  urinary	   frequency	   (34,	   35).	  However,	   the	   side	  effects	  observed	   in	  patients	  
after	  NGF	  sequestration	  and	  in	  animals	  after	  intrathecal	  BDNF	  scavenging	  may	  preclude	  the	  
clinical	  application	  of	  this	  strategy	  (33,	  34)	  
	  
The	  involvement	  of	  the	  sympathetic	  nervous	  system	  in	  BPS/IC	  
Stress	  and	  sympathetic	  activation	  have	  been	  shown	  to	  impair	  the	  immune,	  endocrine	  and	  
nervous	   systems	   and	   can	   be	   an	   important	   factor	   in	   functional	   gastrointestinal	   (GI)	   and	  
genitourinary	  (GU)	  disorders	  such	  as	  IBS	  and	  BPS/IC.	  Rats	  exposed	  to	  various	  types	  of	  stress	  
(water	   avoidance,	   intruder	   stress)	   exhibit	   symptoms	   of	   bladder	   dysfunction	   including	  
increased	   micturition	   frequency	   as	   well	   as	   anxiety-­‐like	   behaviour	   (36,	   37).	   Further,	   an	  
exaggerated	  acoustic	  startle	   response	  has	  been	  demonstrated	   in	  both	  cats	  diagnosed	  with	  
feline	  IC	  as	  well	  as	  in	  BPS/IC	  patients	  (38,	  39).	  	  
The	   importance	   of	   the	   sympathetic	   nervous	   system	   in	   BPS/IC	   has	   been	   traditionally	  
disregarded.	  However,	  the	  density	  of	  sympathetic	  nerve	  fibres	  is	  higher	  in	  bladder	  biopsies	  
from	  BPS/IC	  patients	  (40)	  and	  the	  urinary	  concentration	  of	  catecholamines	  is	  also	  very	  high	  
(41).	  Both	  parameters	  positively	  correlate	  with	  the	  severity	  of	  symptoms	  (42).	  	  
To	  better	  understand	  the	  putative	  role	  of	   the	  sympathetic	  nervous	  system	  in	  BPS/IC,	  our	  
group	  was	  recently	  involved	  in	  a	  study	  analysing	  both	  human	  data	  and	  experimental	  results	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(43).	  In	  BPS/IC	  patients	  noradrenaline	  levels	  in	  blood	  at	  resting	  conditions	  and	  in	  24-­‐hr	  urine	  
were	   higher	   than	   in	   healthy	   controls.	   The	   TILT	   test	   revealed	   sympathetic	   system	  
hyperactivity	  in	  the	  same	  patients	  (Table	  I).	  	  
These	  results	  are	  in	  line	  with	  other	  studies	  that	  demonstrated	  higher	  mean	  blood	  pressure	  
and	  elevated	  heart	  rate	  during	  bladder	  hydrodistention	  in	  BPS/IC	  patients	  (44).	  Altogether,	  
such	   results	   suggest	   that	   sympathetic	   hyperactivity	   may	   be	   an	   important,	   if	   not	   the	   key,	  
cause	   of	   BPS/IC.	   To	   investigate	   a	   possible	   causal	   relation	   adrenergic	   overactivity	   and	   the	  
bladder	   changes	   occurring	   in	   BPS/IC,	  we	   developed	   and	   animal	  model	   in	  which	   rats	  were	  
submitted	   to	   daily	   subcutaneous	   administration	   of	   phenylephrine	   (PHE),	   a	   potent	   non-­‐
catecholamine,	  predominantly	  alpha	  adrenoreceptor	  agonist.	  	  
In	  rats	  submitted	  to	  chronic	  adrenergic	  stimulation	  behavioural	  signs	  of	  pain	  were	  obvious	  
(Fig.	  1)	  and	  accompanied	  by	  increased	  spinal	  Fos	  expression	  (a	  surrogate	  marker	  of	  pain	  at	  
the	  spinal	  cord	  level),	  as	  well	  bladder	  and	  faecal	  hyperactivity.	  	  
Histological	  analysis	  of	  the	  bladder	  identified	  suburothelial	  mastocytosis	  and	  large	  areas	  of	  
reduced	  urothelium	  thickness	  (Fig.	  2A,	  2B),	  similarly	  to	  what	  is	  typically	  observed	  in	  bladder	  
biopsies	  from	  BPS/IC	  patients.	  Also,	  the	  expression	  of	  pro-­‐apoptotic	  markers	  and	  a	  reduction	  
of	   the	  expression	  of	   cytokeratin	  observed	   in	   that	   study	   (Figs.	  2C-­‐E),	   strongly	   suggests	   that	  
sympathetic	   hyperactivation	   is	   the	   underlying	   mechanism	   responsible	   for	   urothelial	  
dysfunction	   in	   BPS/IC	   (45).	   Our	   clinical	   and	   experimental	   observations	   indicate	   that	  
sympathetic	  hyperactivity	   is,	   at	   least,	  partially	   responsible	   for	  BPS/IC.	   The	  proposal	  of	   this	  
novel	  hypothesis	  may	  open	  new	  opportunities	  for	  a	  better	  understanding	  of	  this	  syndrome	  
and	  the	  design	  of	  more	  efficient	  therapeutic	  strategies.	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Discussion	  	  
BPS/IC	  is	  a	  heterogeneous	  syndrome	  and	  available	  studies	  pinpoint	  a	  myriad	  of	  factors	  that	  
may	  contribute	  to	  its	  etiology.	  	  The	  possible	  contribution	  of	  the	  sympathetic	  nervous	  system	  
was	  initially	  raised	  following	  observations	  in	  BPS/IC	  patients	  of	  elevated	  blood	  pressure	  and	  
heart	   rate	  during	  bladder	  distention	   (44)	   	  and	   increased	  sympathetic	   innervation	   (46).	  Our	  
results	  confirmed	  sympathetic	  dysfunction	  in	  BPS/IC	  patients,	  assessed	  both	  by	  the	  TILT	  test	  
and	  the	  high	  urinary	  noradrenaline	  concentration.	  Chronic	  administration	  of	  phenylephrine	  
closely	   replicated	  a	  number	  of	   typical	   findings	   in	  BPS/IC	  patients,	   including	   strong	   visceral	  
pain,	  urothelial	  dysfunction,	  mast	  cell	   infiltration,	  and	  visceral	  dysfunction.	   	   It	   is,	  thus,	  very	  
likely	  that	  sympathetic	  hyperactivity	  is	  at	  the	  root	  of	  BPS/IC.	  	  
Indeed,	  it	  is	  possible	  that	  an	  initial	  hyperactivation	  of	  the	  sympathetic	  system	  may	  initiate	  a	  
cascade	  of	  events	  that	  leads	  to	  BPS/IC.	  Noradrenaline	  release	  in	  the	  bladder	  wall	  may	  active	  
mast	   cells	   and	   lymphocytes,	   known	   to	   express	   alpha-­‐adrenoreptors	   (47).	   These	   cells	  may	  
release	   pro-­‐inflammatory	   elements	   and	   neurotrophins	   that	   may	   act	   on	   bladder	   sensory	  
nerves,	  causing	  pain	  and	  bladder	  dysfunction	  and	  also	  lead	  to	  severe	  urothelial	  damage,	  that	  
also	  contributes	   to	  pain	  and	  bladder	  hyperactivity	   (15,	  18,	  40).	  This	   sympathetic	  mediated	  
release	  of	  mast	   cell	  mediators	   could	   also	   explain	   the	  worsening	  of	  most	   of	   BPS/IC	   clinical	  
symptoms	  in	  stressful	  conditions.	  	  
An	   important	   observation	   is	   that	   chronic	   administration	   of	   PHE	   also	   lead	   to	   faecal	  
hyperactivity,	  which	  is	  reminiscent	  of	  colonic	  hyperactivity,	  or	  even	  the	  presence	  of	  IBS	  (43),	  
in	   BPS/IC	   patients.	   Although	   the	   occurrence	   of	   cross-­‐organ	   sensitization	   can	   be	  
demonstrated	  following	  experimental	  bladder	  or	  colon	  inflammation	  and	  reflect	  dichotomy	  
sensory	  innervation	  of	  both	  organs	  (48),	  one	  could	  speculate	  that	  both	  conditions	  may	  result	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from	  sympathetic	  hyperactivity.	   In	  fact,	  patients	  with	   irritable	  colon	  also	  present	   increased	  
sympathetic	  innervation	  and	  urinary	  noradrenaline	  (49).	  	  
	  
Conclusion	  
BPS/IC	   is	  considered	  a	  multifactorial	  disease.	  The	  role	  of	  the	  sympathetic	  nervous	  system	  
has	   been	   poorly	   investigated	   but	   its	   hyperactivity	   may	   be	   a	   crucial	   event	   for	   the	  
pathophysiology	   of	   BPS/IC.	   This	   may	   have	   important	   clinical	   implications	   as	   different	  
experimental	  and	  clinical	  approaches	  may	  be	  used	  with	  BPS/IC	  patients.	  Further	  research	  is	  
necessary	  not	  only	  to	  identify	  the	  triggering	  event	  leading	  to	  sympathetic	  activation	  but	  also	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   Control	   BPS/IC	  
ΔSDPP	   57.2	  ±723.0	   24.2	  ±	  18.2*	  
rMSSD	   6.3	  ±2.8	   5.6	  ±	  8.4	  
BRS	   7.1	  ±3.8	   7.7	  ±	  8.2	  
24	  hr	  urinary	  NA	  (mg/day)	   47.8	  ±17.8	   102.1	  ±	  43.7*	  
Plasmatic	  NA	  (supine)	  (μg/ml)	   204.3	  ±46.6	   397.0	  ±	  36.4***	  
Plasmatic	  NA	  (upright)	  (μg/ml)	   578.3	  ±69.0	   596.3	  ±	  30.4	  
Table	  I.	  Sympathetic	  overactivity	  in	  IC/BPS	  patients.	  
Standard	   deviation	   of	   the	   P	   wave	   intervals	   (ΔSDPP);	   Root	   mean	   square	  
successive	   differences	   (rMSSD);	   Baroreflex	   sensitivy	   (BRS);	   Noradrenaline	  
(NA).	  
Mean	   values	   of	   observations	   obtained	   during	   TILT	   test,	   and	   noradrenaline	  
quantification	  in	  24	  hr	  urine	  samples	  and	  plasma.	  
ΔSDPP	  was	  used	  to	  record	  the	  increment	  in	  sympathetic	  activity.	  rMSSD	  and	  
BRS	  were	  used	  to	  evaluate	  the	  parasympathetic	  system.	  
*P<0.05.	  
***P<0.001	  
Adapted	  from	  Charrua	  et	  al.	  (2013)	  	  











































Saline	   Phenylphrine	  
Fig.	  1.	  Mechanical	  sensitivity	  of	  the	  lower	  abdomen	  (a)	  and	  hindpaw	  (b)	  
after	   chronic	   phenylephrine	   treatment.	   The	   group	   treated	   with	  phenylephrine	  (PHE)	  had	  a	  significantly	  lower	  threshold	  both	  in	  the	  abdomen	  (a)	  and.in	  hindpaw	  (b).	  The	  increase	  in	  the	  mechanical	  sensitivity	  was	  evident	  from	   the	   1st	   week	   of	   treatment	   onwards	   (p<0.05	   versus	   non-­‐treated	   rats).	  	  This	  indicates	  the	  presence	  of	  visceral	  pain.	  	  *P<0.01	  vs	  saline	  treatment;	  repeated	  measures	  ANOVA	  followed	  by	  Student-­‐Neumman-­‐Keuls.	  Adapted	  from	  Charrua	  et	  al.	  (2013)	  	  
* * * 
* * * 
* 





Fig.	   2.	   Urothelial	   changes	   following	   chronic	   administration	   of	  
phenylephrine.	  A:	  Haemotoxilin/eosing	  staining	  showed	  that	  compared	  with	  controls,	   PHE	   treated	   rat	   bladder	   shows	   a	   reduced	   thickness	   of	   urothelium.	  
B/C:Cytokeratin	   20-­‐positive	   umbrella	   cells	   (in	   red)	   that	   are	   decreased	   or	  absent	   in	   areas	   of	   PHE	   treated	   group	   bladders	   (nuclei	   are	   stained	   in	   blue).	  
D/E:	   Staining	   of	   Caspase	   3	   and	   BAX	   pro-­‐apoptotic	   proteins	   was	   strongly	  increased	  in	  PHE-­‐treated	  rats.	  	  Adapted	  from	  Charrua	  et	  al.	  (2013)	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   publication:	  
Publisher;	  Year.	  
Book	  chapter	  
Author	   Surname	   Initials.	   Chapter	   title.	   In:	   Editor	   Surname	   Initials,	   editor.	   Title:	   subtitle.	  
Edition	  (if	  not	  the	  first).	  Place	  of	  publication:	  Publisher;	  Year.	  Pages.	  
Online	  material	  
Author	   Surname	   Initials	   (if	   available).	   Title	   of	   Website	   [Internet].	   Place	   of	   publication:	  
Publisher;	  Date	  of	  First	  Publication	  [Date	  of	  last	  update;	  cited	  date].	  Available	  from:	  URL	  
MANUSCRIPT	  FORMATTING	  :	  
For	  optimal	  production,	  prepare	  manuscript	  text	  in	  size	  12	  font	  on	  8-­‐1/2	  x	  11	  inch	  page,	  with	  
at	  least	  1	  inch	  margins	  on	  all	  sides.	  
ILLUSTRATIONS	  :	  
The	  minimum	  requirements	  for	  digital	  resolution	  are:	  
• 1200	  DPI/PPI	  for	  black	  and	  white	  images,	  such	  as	  line	  drawings	  or	  graphs.	  
• 300	  DPI/PPI	  for	  picture-­‐only	  photographs	  
• 600	  DPI/PPI	  for	  photographs	  containing	  pictures	  and	  line	  elements,	  i.e.,	  text	  labels,	  thin	  
lines,	  arrows.	  
These	  resolutions	  refer	  to	  the	  output	  size	  of	  the	  file;	  if	  you	  anticipate	  that	  your	  images	  will	  
be	  enlarged	  or	  reduced,	  resolutions	  should	  be	  adjusted	  accordingly.	  
For	   the	  editorial	   review	  process	  EPS	  or	  TIFF	   files	  will	  be	   required	   in	  RGB	  color.	  Delivery	  of	  
these	   production-­‐quality	   files	   early	   in	   the	   review	  process	  may	   facilitate	   smooth	   and	   rapid	  
publication	  once	  a	  manuscript	  has	  been	  accepted.	  
Four-­‐color	  illustrations	  will	  be	  considered	  for	  print	  publication.	  However,	  the	  author	  will	  be	  
required	  to	  bear	  the	  cost	  of	  their	  reproduction.	  The	  charge	  for	  each	  page	  of	  color	  is	  $250.	  
All	  color	  figures	  will	  be	  reproduced	  in	  full	  color	   in	  the	  online	  edition	  of	  the	   journal	  at	  no	  
cost	  to	  authors.	  As	  noted	  previously,	  authors	  are	  requested	  to	  pay	  the	  cost	  of	  reproducing	  
color	   figures	   in	  print.	  Authors	  are	  encouraged	   to	   submit	   color	   illustrations	   that	  highlight	  
the	   text	   and	   convey	   essential	   scientific	   information.	   For	   best	   reproduction,	   bright,	   clear	  
colors	   should	   be	   used.	   Dark	   colors	   against	   a	   dark	   background	   do	   not	   reproduce	   well;	  
please	  place	  your	  color	  images	  against	  a	  white	  background	  wherever	  possible.	  
SUPPORTING	  INFORMATION	  :	  
Supporting	  Information	  can	  be	  a	  useful	  way	  for	  an	  author	  to	  include	  important	  but	  ancillary	  
information	   with	   the	   online	   version	   of	   an	   article.	   Examples	   of	   Supporting	   Information	  
include	  additional	  tables,	  data	  sets,	  figures,	  movie	  files,	  audio	  clips,	  3D	  structures,	  and	  other	  
related	   nonessential	   multimedia	   files.	   Supporting	   Information	   should	   be	   cited	   within	   the	  
article	   text,	  and	  a	  descriptive	   legend	  should	  be	   included.	   It	   is	  published	  as	  supplied	  by	   the	  
author,	   and	   a	   proof	   is	   not	  made	   available	   prior	   to	   publication;	   for	   these	   reasons,	   authors	  
should	  provide	  any	  Supporting	  Information	  in	  the	  desired	  final	  format.	  	  
For	  further	  information	  on	  recommended	  file	  types	  and	  requirements	  for	  submission,	  please	  
visit:	  http://authorservices.wiley.com/bauthor/suppinfo.asp	  
	  
CATEGORY	  OF	  SUBMISSIONS	  :	  
The	   Journal	   accepts	   papers	   prepared	   in	   any	   one	   of	   the	   following	   forms	   listed	   below.	  	   For	  
clinical	   papers	   dealing	   with	   the	   treatment	   of	   urinary	   incontinence	   and/or	   pelvic	   organ	  
prolapse,	  preference	  will	  be	  given	  to	  papers	  whose	  methodology	  and	  terminology	  adheres	  
to	  existing	  ICS	  and	  SUFU	  guidelines	  (www.icsoffice.org	  and	  www.sufuorg.com).	  
State	  of	  the	  art	  review	  articles.	  Review	  articles	  will	  be	  solicited	  by	  a	  panel	  of	  editors,	  or	  may	  
be	   submitted	  directly	   to	   the	  editor	  by	   the	  author.	   They	  are	  designed	   to	  provide	  an	  up-­‐to-­‐
date	   review	   of	   the	   most	   modern	   and	   reasonable	   approach	   to	   a	   particular	   topic	   by	   a	  
recognized	  expert	  in	  the	  field.	  They	  represent	  the	  authors'	  editorial	  point	  of	  view	  rather	  than	  
a	   litany	  of	  dogma	  or	  an	  exhaustive	  compilation	  of	  all	  prior	  work	   in	  that	  field.	  These	  should	  
not	  exceed	  3000	  words	  and	  50	  references.	  
Authors	  of	  systematic	  reviews	  must	  include	  a	  PRISMA	  checklist	  as	  part	  of	  their	  submission.	  
Further	  details	  of	  the	  PRISMA	  requirements,	  flow	  charts	  and	  a	  Word	  version	  of	  the	  checklist	  
are	   available	   at:	  http://www.prisma-­‐statement.org/	  The	   checklist	   is	   also	   available	   to	  
download	   from	   the	  Neurourology	  &	  Urodynamics	   ScholarOne	  Manuscripts	  website	   during	  
paper	  submission.	  
Original	  basic	  science	  articles	  and	  original	  clinical	  articles.	  Only	  those	  articles	  that	  meet	  the	  
high	  standards	  of	  the	  editorial	  board	  will	  be	  published	  in	  this	  section.	  When	  received,	  papers	  
are	  assigned	  to	  an	  associate	  editor,	  who	  will	  select	  two	  additional	  referees	  for	  final	  review.	  
These	   should	   not	   exceed	   3000	   words	   and	   25	   references.	   The	   clinical	   trial	   registration	  
number	   must	   be	   reported	   in	   the	   cover	   letter	   for	   all	   submissions	   of	   clinical	   trial	  
articles.	  	  Trials	  that	  are	  not	  registered	  will	  not	  be	  published,	  consistent	  with	  the	  International	  
Committee	   of	  Medical	   Journal	   Editors’	   Uniform	   Requirements	   (	  www.icmje.org	  ).	  	   Authors	  
are	   also	   encouraged	   to	   consult	   reporting	   guidelines	   relevant	   to	   their	   specific	   research	  
design.	   For	   reports	   of	   randomized	   controlled	   trials	   authors	   must	   refer	   to	   the	   CONSORT	  
statement	  (	  www.consort-­‐statement.org	  ).	  
Sounding	   board.	  This	   section	   is	   appropriate	   for	   papers	   that	   present	   an	   opinion,	   point	   of	  
view,	  new	  concept,	  idea	  or	  editorial.	  	  They	  will	  be	  reviewed	  by	  the	  Editor	  in	  Chief,	  Associate	  
Editors,	  and,	  when	  appropriate,	  they	  may	  be	  assigned	  to	  other	  reviewers.	  	  As	  far	  as	  possible	  
the	  editors	  will	  respect	  the	  editorial	  integrity	  and	  style	  of	  the	  author.	  
Controversies	   in	   neurourology.	  Controversial	   topics	   will	   be	   presented	   by	   two	   or	   more	  
authors	  who	  take	  different	  points	  of	  view.	  The	  authors	  will	  be	  solicited	  by	  the	  core	  editorial	  
team	  and	  the	  discussion	  moderated	  by	  Jerry	  Blaivas.	  	  
Letters	   to	   the	  editor.	  Pertinent	   letters	  of	   interest	  to	  the	  readership	  should	  not	  exceed	  800	  
words.	  	  Peer-­‐review	  will	  consist	  of	  approval	  by	  the	  Editor	   in	  Chief	  and	  a	  response	  from	  the	  
author	   of	   any	   paper	   the	   letter	   comments	   on.	  	   If	   the	   letter	   does	   not	   follow	   the	   above	  
guidelines,	  it	  will	  have	  to	  be	  submitted	  for	  formal	  peer	  review.	  
Editorial	  Comments.	  	  	  If	  it	  is	  appropriate	  for	  an	  editorial	  comment	  to	  accompany	  a	  particular	  
article,	   this	   will	   be	   solicited	   by	   the	   core	   editorial	   team.	  	   Editorial	   comments	   should	   not	  
exceed	  500-­‐600	  words.	  
NB.	  Unfortunately,	  we	  cannot	  accept	  Case	  Reports.	  
	  
ETHICAL	  CONSIDERATIONS	  :	  
Neurourology	   and	   Urodynamics	  believes	   in	   ethical	   behavior	   and	   supports	   the	  
ICMJE	  Uniform	   Requirements	   (www.icmje.org	  )	   the	   CONSORT	   statement	   (	  www.consort-­‐
statement.org	  )	  and	  the	  COPE	  guidelines	  (	  www.publicationethics.org.uk	  ).	  
The	  Editor	   In	  Chief	  and	  Associate	  Editors	  have	  full	  responsibility	  and	  independence	  in	  both	  
intellectual	   and	   practical	   terms	   to	   determine	   the	   content	   and	   academic	   direction	   of	   the	  
journal,	   with	   particular	   reference	   to	   the	   validity	   of	   work	   and	   its	   importance	   to	   journal	  
readers.	   All	   articles	  will	   be	   peer-­‐reviewed	   in	   a	   blinded	   fashion.	  	   Supervision	   of	   the	   review	  
process	  will	   either	   be	   via	   the	   Editor	   in	   Chief	   or	   a	   designated	  Associate	   Editor.	  	  We	   aim	   to	  
have	  a	  minimum	  of	  two	  reviews	  carried	  out	  and	  often	  more	  than	  this.	  	  Reviewers’	  opinions	  
are	   relied	   upon	   heavily,	   but	   the	   final	   decision	   as	   to	  what	   is	   published	   rests	  with	   the	   core	  
editorial	   team.	  	  All	   authors	  have	   the	   right	   to	   appeal	   editorial	   decisions	   and	  we	  are	   always	  
willing	   to	   receive	   and	   deal	   with	   these.	   Corrections	   of	   errors	   (where	   they	   affect	   the	  
interpretation	  of	  data	  or	  information)	  will	  be	  published	  as	  referenced	  errata.	  
Neurourology	  and	  Urodynamics	  employs	  a	  plagiarism	  detection	  system.	  By	  submitting	  your	  
manuscript	  to	  this	  journal,	  you	  accept	  that	  your	  manuscript	  may	  be	  screened	  for	  plagiarism	  
against	  previously	  published	  works.	  
Scientific	   Fraud.	  Whenever	   scientific	   fraud	   of	   any	   sort,	   including	   dual	   publication,	   is	  
suspected,	  it	  should	  be	  reported	  back	  to	  the	  Editor	  in	  Chief,	  who	  will	  then	  discuss	  it	  with	  the	  
Associate	  Editors	  and	  if	  there	  is	  a	  strong	  case	  that	  fraud	  has	  occurred,	  then	  the	  author	  will	  
be	   contacted.	  	   Unless	   there	   is	   a	   satisfactory	   explanation,	   then	   they	   will	   be	   censured	   by	  
contacting	   the	   Dean	   of	   their	   institution	   with	   the	   facts	   as	   they	   exist,	   and	   instituting	  
immediate	   embargo	   on	   any	   further	   work	   from	   them	   for	   a	   minimum	   of	   two	  
years.	  	   Consideration	   will	   also	   need	   to	   be	   given	   to	   contacting	   editors	   of	   other	   major	  
urological	  journals	  to	  inform	  them	  of	  this	  problem,	  on	  a	  confidential	  basis.	  
All	   manuscripts	   submitted	   to	  Neurourology	   and	   Urodynamics	  must	   be	   submitted	   solely	   to	  
this	  journal	  and	  may	  not	  have	  been	  published	  in	  any	  part	  or	  form	  in	  another	  publication	  of	  
any	  type,	  professional	  or	  lay,	  and	  become	  the	  property	  of	  the	  publisher.	  On	  acceptance	  of	  a	  
manuscript	  for	  publication,	  authors	  will	  be	  asked	  to	  transfer	  copyright	  to	  the	  publisher,	  who	  
reserves	   copyright.	   No	   published	   material	   may	   be	   reproduced	   or	   published	   elsewhere	  
without	   the	   written	   permission	   of	   the	   publisher	   and	   the	   author.	   The	   Journal	   will	   not	   be	  
responsible	   for	   the	   loss	   of	  manuscripts	   at	   any	   time.	   All	   statements	   in,	   or	   omissions	   from,	  
published	  manuscripts	   are	   the	   responsibility	   of	   the	   authors,	  who	  will	   assist	   the	   editors	   by	  
reviewing	   proofs	   before	   publication.	   Reprint	   order	   forms	  will	   be	   sent	  with	   the	   proofs.	  No	  
page	  charges	  will	  be	  levied	  against	  authors	  or	  their	  institutions	  for	  publication	  in	  this	  journal.	  
	  
	  
COPYRIGHT	  and	  ONLINE	  OPEN:	  
If	  your	  paper	   is	  accepted,	  the	  author	   identified	  as	  the	  formal	  corresponding	  author	  for	  the	  
paper	   will	   receive	   an	   email	   prompting	   them	   to	   login	   into	   Author	   Services;	   where	   via	   the	  
Wiley	  Author	  Licensing	  Service	  (WALS)	  they	  will	  be	  able	  to	  complete	  the	  license	  agreement	  
on	  behalf	  of	  all	  authors	  on	  the	  paper.	  
For	  authors	  signing	  the	  copyright	  transfer	  agreement	  
If	   the	  OnlineOpen	  option	   is	   not	   selected	   the	   corresponding	   author	  will	   be	  presented	  with	  
the	  copyright	  transfer	  agreement	  (CTA)	  to	  sign.	  The	  terms	  and	  conditions	  of	  the	  CTA	  can	  be	  
previewed	  in	  the	  samples	  associated	  with	  the	  Copyright	  FAQs	  below:	  
CTA	  Terms	  and	  Conditions	  http://authorservices.wiley.com/bauthor/faqs_copyright.asp	  
For	  authors	  choosing	  OnlineOpen	  
If	   the	   OnlineOpen	   option	   is	   selected	   the	   corresponding	   author	   will	   have	   a	   choice	   of	   the	  
following	  Creative	  Commons	  License	  Open	  Access	  Agreements	  (OAA):	  
Creative	  Commons	  Attribution	  
Non-­‐Commercial	  License	  OAA	  
Creative	  Commons	  Attribution	  Non-­‐Commercial	  -­‐NoDerivs	  License	  OAA	  
To	   preview	   the	   terms	   and	   conditions	   of	   these	   open	   access	   agreements	   please	   visit	   the	  




If	  you	  select	  the	  OnlineOpen	  option	  and	  your	  research	  is	  funded	  by	  The	  Wellcome	  Trust	  and	  
members	  of	   the	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